Antares Therapeutics
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $177.0Mattributed |
|---|---|
| Latest round | series-a, $177.0M, 2025-06-01attributed |
| Founded | 2025 |
| Headquarters | Boston USA |
| Industry | bio |
| Stage | series-a |
| Website | antaresrx.com |
Precision oncology biotech developing small-molecule drugs for cancer and other serious diseases, spun out of Lilly's Scorpion Therapeutics acquisition with $177M funding. Targets pharma partners and patients with previously undruggable cancer targets. First clinical trial expected in 2026 from an integrated medicinal chemistry and predictive science platform.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-06-01 | series-a | $177.0M | undisclosed |
Detected tech stack
Nginx, Akismet, Google Analytics, Google Tag Manager, DoubleClick Floodlight, Contact Form 7 6.1.6, WordPress, WordPress Block Editor, WP Rocket 3.21.3, wp.cloud, PHP, MySQL
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $177.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $177.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | antaresrx.com, read 2026-05-02 |
| Description | self-reported | antaresrx.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.